Preview

Архивъ внутренней медицины

Расширенный поиск

Фактор некроза опухоли-альфа и возрастассоциированная патология

https://doi.org/10.20514/2226-6704-2020-10-6-414-421

Полный текст:

Аннотация

В обзоре отражены современные представления о понятии «inflammaging» и роли субклини ческого воспаления при различной возрастассоциированной патологии. Особое внимание уделено фактору некроза опухоли-α — ключевому цитокину, принимающему важное участие как в патогенезе хронических воспалительных заболеваний, так и в процессах старения. Повышенное содержание фактора некроза опухоли-α приводит к возникновению и прогрессированию различных заболеваний, к усугублению старческой астении, к инвалидизации и смертности лиц пожилого и старческого возраста. Фактор некроза опухоли-α оказывает влияние на различные факторы риска сердечно-сосудистой патологии, способствует возникновению и прогрессированию атеросклероза и связанных с ним заболеваний. Этот цитокин может усугублять также различные метаболические нарушения, в первую очередь, инсулинорезистентность и сахарный диабет. Фактор некроза опухоли-α — ключевой цитокин, стимулирующий костную резорбцию (с возникновением остеопороза) и саркопению. Имеющиеся в нас тоящее время данные подтверждают важную роль фактора некроза опухоли-α при различных возраст-ассоциированных заболеваниях.

Об авторе

С. В. Тополянская
ФГАОУ ВО Первый Московский государственный медицинский университет имени И.М. Сеченова Министерства здравоохранения РФ (Сеченовский Университет)
Россия

Светлана Викторовна Тополянская

Кафедра госпитальной терапии № 2

Москва



Список литературы

1. Franceschi C., Bonafe M., Valentin S., et al. Inflamm-aging. An evolutionary perspective on immunosenescence. Ann N Y Acad Sci. 2000;908:244-54. DOI: 10.1111/j.1749-6632.2000.tb06651.x.

2. Xia S., Zhang X., Zheng S., et al. An Update on Inflamm-Aging: Mechanisms, Prevention, and Treatment. J. Immunol. Res. 2016; 2016(8):1–8. DOI:10.1155/2016/8426874.

3. Minciullo P.L., Catalano A., Mandraffino G., et al. Inflammaging and Anti-Inflammaging: The Role of Cytokines in Extreme Longevity. Arch. Immunol. Ther. Exp. (Warsz). 2016;64(2):111– 26. DOI: 10.1007/s00005-015-0377-3.

4. Franceschi C., Capri M., Monti D., et al. Inflammaging and anti-inflammaging: A systemic perspective on aging and longevity emerged from studies in humans. Mech. Ageing Dev. 2007;128(1):92–105. DOI: 10.1016/j.mad.2006.11.016.

5. Franceschi C., Olivieri F., Marchegiani F., et al. Genes involved in immune response/inflammation, IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: The lesson of centenarians. Mechanisms of Ageing and Development. 2005;126 (2):351-61. DOI: 10.1016/j.mad.2004.08.028.

6. Bruunsgaard H., Andersen-Ranberg K., Hjelmborg J.V.B., et al. Elevated levels of tumor necrosis factor alpha and mortality in centenarians. Am J Med. 2003;115(4):278-83. DOI:10.1016/S0002-9343(03)00329-2.

7. Bruunsgaard H., Ladelund S., Pedersen A.N., et al. Predicting death from tumour necrosis factor-alpha and interleukin-6 in 80-year-old people. Clin Exp Immunol. 2003;132:24-31. DOI:10.1046/j.1365-2249.2003.02137.x.

8. Kany S., Vollrath J.T., Relja B. Cytokines in inflammatory disease. International Journal of Molecular Sciences. 2019;20(23):6008. DOI: 10.3390/ijms20236008.

9. Urschel K., Cicha I. TNF-α in the cardiovascular system: From physiology to therapy. International Journal of Interferon, Cytokine and Mediator Research. 2015;7:9–25. DOI: 10.2147/IJICMR.S64894.

10. Wallach D. The cybernetics of TNF: Old views and newer ones. Seminars in Cell and Developmental Biology. 2016;50:105–14. DOI: 10.1016/j.semcdb.2015.10.014.

11. Bradley J. TNF-mediated inflammatory disease. J. Pathol. 2008;214(2):149-60. DOI: 10.1002/path.2287.

12. Rea I.M., Gibson D.S., McGilligan V., et al. Age and age-related diseases: Role of inflammation triggers and cytokines. Front Immunol. 2018;9(9):586. DOI:10.3389/fimmu.2018.00586.

13. Brüünsgaard H., Pedersen B.K. Age-related inflammatory cytokines and disease. Immunol. Allergy Clin. North Am. 2003;23(1):15–39. DOI: 10.1016/S0889-8561(02)00056-5.

14. Roubenoff R., Parise H., Payette H., et al. Cytokines, insulinlike growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: The Framingham Heart Study. Am. J. Med. Elsevier Inc. 2003;115(6):429–35. DOI: 10.1016/j.amjmed.2003.05.001.

15. Bruunsgaard H., Benfield T.L., Andersen-Ranberg K., et al. The tumor necrosis factor alpha — 308G > a polymorphism is associated with dementia in the oldest old. J. Am. Geriatr. Soc. 2004;52 (8):1361–6. DOI: 10.1111/j.1532-5415.2004.52369.x.

16. Cederholm T., Persson M., Andersson P., et al. Polymorphisms in cytokine genes influence long-term survival differently in elderly male and female patients. J. Intern. Med. 2007;262 (2):215-23. DOI: 10.1111/j.1365-2796.2007.01803.x.

17. Zhang P., Wu X., Li G., et al. Tumor necrosis factor-alpha gene polymorphisms and susceptibility to ischemic heart disease. Medicine (United States). 2017;96(14):e6569. DOI: 10.1097/MD.0000000000006569.

18. Bruunsgaard H., Skinhoj P., Pedersen A.N., et al. Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis. Clin. Exp. Immunol. 2000;121(2):255–60. DOI: 10.1046/j.1365-2249.2000.01281.x.

19. Ait-Oufella H., Taleb S., Mallat Z., et al. Recent advances on the role of cytokines in atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2011;31(5):969-79. DOI: 10.1161/ATVBAHA.110.207415.

20. Kim H.L., Lee J.P., An J.N., et al. Soluble tumor necrosis factor receptors and arterial stiffness in patients with coronary atherosclerosis. Am. J. Hypertens. 2017;30(3):313–8. DOI: 10.1093/ajh/hpw134.

21. Kaptoge S., Seshasai S.R.K., Gao P., et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. Eur Heart J. 2014;35(9):578-89. DOI: 10.1093/eurheartj/eht367.

22. Heinisch R.H., Zanetti C.R., Comin F., et al. Serial changes in plasma levels of cytokines in patients with coronary artery disease. Vasc. Health Risk Manag. 2005;1(3):245–50.

23. Moreira D.M., da Silva R.L., Vieira J.L., et al. Role of Vascular Inflammation in Coronary Artery Disease: Potential of Antiinflammatory Drugs in the Prevention of Atherothrombosis: Inflammation and Anti-Inflammatory Drugs in Coronary Artery Disease. Am. J. Cardiovasc. Drugs. 2015;15(1):1-11. DOI: 10.1007/s40256-014-0094-z.

24. Chia S., Qadan M., Newton R., et al. Intra–arterial tumor necrosis factor–α impairs endothelium–dependent vasodilatation and stimulates local tissue plasminogen activator release in humans. Arterioscler Thromb Vasc Biol. 2003; 23(4): 695–701. DOI: doi.org/10.1161/01.ATV.0000065195.22904.FA

25. Nakamura M., Yoshida H., Arakawa N., et al. Effects of tumor necrosis factor-α on basal and stimulated endothelium-dependent vasomotion in human resistance vessel. J. Cardiovasc. Pharmacol. 2000;36(4):487-92. DOI: 10.1097/00005344-200010000-00011.

26. Fang W., Wei J., Han D., et al. MC-002 exhibits positive effects against platelets aggregation and endothelial dysfunction through thromboxane A2 inhibition. Thromb. Res. 2014;133(4):610-5. DOI: 10.1016/j.thromres.2014.01.029.

27. Sun M., Dawood F., Wen W.H., et al. Excessive tumor necrosis factor activation after infarction contributes to susceptibility of myocardial rupture and left ventricular dysfunction. Circulation. 2004;110(20):3221-8. DOI: 10.1161/01.CIR.0000147233.10318.23.

28. Ridker P.M., Rifai N., Pfeffer M., et al. Elevation of tumor necrosis factor-α and increased risk of recurrent coronary events after myocardial infarction. Circulation. 2000;101(18):2149–53. DOI: 10.1161/01.cir.101.18.2149.

29. Schumacher S.M., Naga Prasad S.V. Tumor Necrosis Factor-α in Heart Failure: An updated review. Curr Cardiol Rep. 2018;20 (11):117. DOI: 10.1007/s11886-018-1067-7.

30. Zhu J.X., Liu M.Y., Kennedy R.H., et al. TNF-α-induced impairment of mitochondrial integrity and apoptosis mediated by caspase-8 in adult ventricular myocytes. Cytokine. 2006;34(1-2):96-105. DOI: 10.1016/j.cyto.2006.04.010.

31. Awad A.E., Kandalam V., Chakrabarti S., et al. Tumor necrosis factor induces matrix metalloproteinases in cardiomyocytes and cardiofibroblasts differentially via superoxide production in a PI3Kγ-dependent manner. Am. J. Physiol. — Cell Physiol. 2010;298(3):679-92. DOI: 10.1152/ajpcell.00351.2009.

32. Flesch M., Hoper A., Dell’Italia L., et al. Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2003;108(5):598-604. DOI: 10.1161/01.CIR.0000081768.13378.BF.

33. Tromp J., Khan M.A., Klip U.T., et al. Biomarker profiles in heart failure patients with preserved and reduced ejection fraction. J. Am. Heart Assoc. 2017;6(4):e003989. DOI: 10.1161/JAHA.116.003989.

34. Senni M., D’Elia E., Emdin M., et al. Biomarkers of heart failure with preserved and reduced ejection fraction. Handb. Exp. Pharmacol. 2017;243:79–108. DOI: 10.1007/164_2016_86.

35. Putko B.N., Wang Z., Lo J., et al. Circulating Levels of Tumor Necrosis Factor-Alpha Receptor 2 Are Increased in Heart Failure with Preserved Ejection Fraction Relative to Heart Failure with Reduced Ejection Fraction: Evidence for a Divergence in Pathophysiology. PLoS One. 2014;9(6):e99495. DOI: 10.1371/journal.pone.0099495.

36. Bozkurt B., Mann D.L., Deswal A. Biomarkers of inflammation in heart failure. Heart Failure Reviews. 2010;15(4):331–41. DOI: 10.1007/s10741-009-9140-3.

37. Ueland T., Gullestad L., Nymo S.H., et al. Inflammatory cytokines as biomarkers in heart failure. Clin. Chim. Acta. 2015;443:71–7. DOI: 10.1016/j.cca.2014.09.001.

38. Vaz Pérez A., Doehner W., Haehling S., et al. The relationship between tumor necrosis factor-α, brain natriuretic peptide and atrial natriuretic peptide in patients with chronic heart failure. Int. J. Cardiol. 2010;141(1):39–43. DOI: 10.1016/j.ijcard.2008.11.146.

39. Ren M., Li X., Hao L., Zhong J.. Role of tumor necrosis factor alpha in the pathogenesis of atrial fibrillation: A novel potential therapeutic target? Ann. Med. Informa Healthcare. 2015;47(4):316–24. DOI: 10.3109/07853890.2015.1042030.

40. Scott L., Li N., Dobrev D. Role of inflammatory signaling in atrial fibrillation. Int. J. Cardiol. 2019;287:195–200. DOI: 10.1016/j.ijcard.2018.10.020.

41. Bradham W.S., Bozkurt B., Gunasinghe H., et al. Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: A current perspective. Cardiovasc. Res. 2002. 53 (4): 822-830. DOI: 10.1016/s0008-6363(01)00503-x.

42. Deng H., Xue Y.M., Zhan X.Z., et al. Role of tumor necrosis factor-alpha in the pathogenesis of atrial fibrillation. Chin Med J (Engl). 2011;124(13):1976-82. DOI: 10.3760/cma.j.issn.0366-6999.2011.13.010.

43. Bautista L.E., Vera L.M., Arenas I.A., et al. Independent association between inflammatory markers (C-reactive protein, interleukin-6, and TNF-α) and essential hypertension. J. Hum. Hypertens. 2005;19(2):149–54. DOI: 10.1038/sj.jhh.1001785.

44. Satou R., Miyata K., Katsurada A., et al. Tumor necrosis factor-α suppresses angiotensinogen expression through formation of a p50/p50 homodimer in human renal proximal tubular cells. Am. J. Physiol. — Cell Physiol. 2010;299(4):750-9. DOI: 10.1152/ajpcell.00078.2010.

45. Zhang W., Li X.-J., Zeng X., et al. Activation of nuclear factor-κB pathway is responsible for tumor necrosis factor-α-induced up-regulation of endothelin B2 receptor expression in vascular smooth muscle cells in vitro. Toxicol. Lett. 2012;209(2):107-12. DOI: 10.1016/j.toxlet.2011.12.005.

46. Jayaraj R.L., Azimullah S., Beiram R., et al. Neuroinflammation: Friend and foe for ischemic stroke. J. Neuroinflammation. 2019;16(1):142. DOI: 10.1186/s12974-019-1516-2.

47. Swaroop J.J., Rajarajeswari D., Naidu J.N. Association of TNF-α with insulin resistance in type 2 diabetes mellitus. Indian J. Med. Res. 2012;135(1):127-30. DOI: 10.4103/0971-5916.93435.

48. Akash M.S.H., Rehman K., Liaqat A. Tumor Necrosis FactorAlpha: Role in Development of Insulin Resistance and Pathogenesis of Type 2 Diabetes Mellitus. J. Cell. Biochem. 2018;119(1):105–10. DOI: 10.1002/jcb.26174.

49. Zhang L., Wheatley C.M., Richards S.M., et al. TNF-α acutely inhibits vascular effects of physiological but not high insulin or contraction. Am. J. Physiol. — Endocrinol. Metab. 2003;285(3):E654-660. DOI: 10.1152/ajpendo.00119.2003.

50. Li G., Barrett E.J., Barrett M.O., et al. Tumor necrosis factor-α induces insulin resistance in endothelial cells via a p38 mitogen-activated protein kinase-dependent pathway. Endocrinology. 2007;148(7):3356-63. DOI: 10.1210/en.2006-1441.

51. Amdur R.L., Feldman H.I., Gupta J., et al. Inflammation and progression of CKD: The CRIC study. Clin J Am Soc Nephrol. 2016;11(9):1546-56. DOI: 10.2215/CJN.13121215.

52. Yu X., Yang Z., Yu M. Correlation of tumor necrosis factor alpha and interleukin 6 with hypertensive renal damage. Ren. Fail. 2010;32:475–9. DOI: 10.3109/08860221003664280.

53. Carlsson A.C., Larsson T.E., Helmersson-Karlqist J., et al. Soluble TNF Receptors and Kidney Dysfunction in the Elderly. J Am Soc Nephrol. 2014;25(6);1313–20. DOI: 10.1681/ASN.2013080860.

54. Zhao B. TNF and Bone Remodeling. Curr. Osteoporos. Rep. 2017;15(3):126–34. DOI: 10.1007/s11914-017-0358-z.

55. Reid M.B., Li Y.P. Tumor necrosis factor-α and muscle wasting: A cellular perspective. Respir. Res. 2001;2(5):269–72. DOI: 10.1186/rr67.

56. Michaud M., Balardy L., Moulis G., et al. Proinflammatory cytokines, aging, and age-related diseases. J. Am. Med. Dir. Assoc. 2013;14(12):877–82. DOI: 10.1016/j.jamda.2013.05.009.

57. Marzetti E., Calvani R., Cesari M., et al. Mitochondrial dysfunction and sarcopenia of aging: from signaling pathways to clinical trials. Int. J. Biochem. Cell Biol. 2013;45(10):2288- 301. DOI: 10.1016/j.biocel.2013.06.024.

58. MacCiò A., Madeddu C. Management of Anemia of inflammation in the elderly. Anemia. 2012; 2012:563251. DOI: 10.1155/2012/563251.

59. Davizon-Castillo P., McMahon D., Aguila S., et al. TNF-αdriven inflammation and mitochondrial dysfunction define the platelet hypereactivity of aging. Blood. 2019:134(9):727-40. DOI: 10.1182/blood.2019000200.

60. Lindbergh C.A., Casaletto K.B., Staffaroni A.M., et al. Systemic tumor necrosis factor-alfa trajectories relate to brain health in typically aging older adults. The Journals of Gerontology: Series A. 2019;glz209. DOI: 10.1093/gerona/glz209.


Для цитирования:


Тополянская С.В. Фактор некроза опухоли-альфа и возрастассоциированная патология. Архивъ внутренней медицины. 2020;10(6):414-421. https://doi.org/10.20514/2226-6704-2020-10-6-414-421

For citation:


Topolyanskaya S.V. Tumor Necrosis Factor-Alpha and Age-Related Pathologies. The Russian Archives of Internal Medicine. 2020;10(6):414-421. https://doi.org/10.20514/2226-6704-2020-10-6-414-421

Просмотров: 180


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2226-6704 (Print)
ISSN 2411-6564 (Online)